Huijbers EJM - Search Results

1

Vaccination against galectin-1 promotes cytotoxic T-cell infiltration in melanoma and reduces tumor burden.

Femel J, van Hooren L, Herre M, Cedervall J, Saupe F, Huijbers EJM, Verboogen DRJ, Reichel M, Thijssen VL, Griffioen AW, Hellman L, Dimberg A, Olsson AK. Femel J, et al. Among authors: huijbers ejm. Cancer Immunol Immunother. 2022 Aug;71(8):2029-2040. doi: 10.1007/s00262-021-03139-4. Epub 2022 Jan 11. Cancer Immunol Immunother. 2022. PMID: 35018481 Free PMC article.

2

Identification of potent biodegradable adjuvants that efficiently break self-tolerance--a key issue in the development of therapeutic vaccines.

Ringvall M, Huijbers EJ, Ahooghalandari P, Alekseeva L, Andronova T, Olsson AK, Hellman L. Ringvall M, et al. Vaccine. 2009 Dec 10;28(1):48-52. doi: 10.1016/j.vaccine.2009.09.122. Epub 2009 Oct 25. Vaccine. 2009. PMID: 19835827

3

Vaccination against the extra domain-B of fibronectin as a novel tumor therapy.

Huijbers EJ, Ringvall M, Femel J, Kalamajski S, Lukinius A, Abrink M, Hellman L, Olsson AK. Huijbers EJ, et al. FASEB J. 2010 Nov;24(11):4535-44. doi: 10.1096/fj.10-163022. Epub 2010 Jul 15. FASEB J. 2010. PMID: 20634349

4

The non-toxic and biodegradable adjuvant Montanide ISA 720/CpG can replace Freund's in a cancer vaccine targeting ED-B--a prerequisite for clinical development.

Huijbers EJ, Femel J, Andersson K, Björkelund H, Hellman L, Olsson AK. Huijbers EJ, et al. Vaccine. 2012 Jan 5;30(2):225-30. doi: 10.1016/j.vaccine.2011.11.010. Epub 2011 Nov 10. Vaccine. 2012. PMID: 22079080

5

Therapeutic vaccination against fibronectin ED-A attenuates progression of metastatic breast cancer.

Femel J, Huijbers EJ, Saupe F, Cedervall J, Zhang L, Roswall P, Larsson E, Olofsson H, Pietras K, Dimberg A, Hellman L, Olsson AK. Femel J, et al. Oncotarget. 2014 Dec 15;5(23):12418-27. doi: 10.18632/oncotarget.2628. Oncotarget. 2014. PMID: 25360764 Free PMC article.

6

Vaccination approach to anti-angiogenic treatment of cancer.

Wentink MQ, Huijbers EJ, de Gruijl TD, Verheul HM, Olsson AK, Griffioen AW. Wentink MQ, et al. Biochim Biophys Acta. 2015 Apr;1855(2):155-71. doi: 10.1016/j.bbcan.2015.01.005. Epub 2015 Jan 30. Biochim Biophys Acta. 2015. PMID: 25641676 Review.

7

The great escape; the hallmarks of resistance to antiangiogenic therapy.

van Beijnum JR, Nowak-Sliwinska P, Huijbers EJ, Thijssen VL, Griffioen AW. van Beijnum JR, et al. Pharmacol Rev. 2015;67(2):441-61. doi: 10.1124/pr.114.010215. Pharmacol Rev. 2015. PMID: 25769965 Review.

8

Vaccines targeting self-antigens: mechanisms and efficacy-determining parameters.

Saupe F, Huijbers EJ, Hein T, Femel J, Cedervall J, Olsson AK, Hellman L. Saupe F, et al. FASEB J. 2015 Aug;29(8):3253-62. doi: 10.1096/fj.15-271502. Epub 2015 Apr 13. FASEB J. 2015. PMID: 25868727

9

CD44 enhances tumor aggressiveness by promoting tumor cell plasticity.

Paulis YW, Huijbers EJ, van der Schaft DW, Soetekouw PM, Pauwels P, Tjan-Heijnen VC, Griffioen AW. Paulis YW, et al. Oncotarget. 2015 Aug 14;6(23):19634-46. doi: 10.18632/oncotarget.3839. Oncotarget. 2015. PMID: 26189059 Free PMC article.

10

Role of the tumor stroma in resistance to anti-angiogenic therapy.

Huijbers EJ, van Beijnum JR, Thijssen VL, Sabrkhany S, Nowak-Sliwinska P, Griffioen AW. Huijbers EJ, et al. Drug Resist Updat. 2016 Mar;25:26-37. doi: 10.1016/j.drup.2016.02.002. Epub 2016 Feb 24. Drug Resist Updat. 2016. PMID: 27155374 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

35 results

Search Page